At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
sugammadex +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sugammadex Versus Neostigmine After Rocuronium Infusion During Liver Transplantation
Azienda Ospedaliera S. Maria della Misericordia·interventional·Posted Mar 3, 2016·Updated Sep 21, 2021
In Brief
A clinical study evaluating sugammadex and Neostigmine for Postoperative Residual Curarization and Liver Transplantation. Completed, enrolled 40 participants across 1 site.
Detailed Summary
Cirrhotic patients undergoing liver transplantation are at very high risk of post operative complication such as post-operative residual curarization. Rocuronium is a neuromuscular blocking agent that nowadays can be safely and rapidly antagonized with sugammadex. No one study compared sugammadex versus neostigmine after rocuronium infusion during liver transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedMar 2016
Primary CompletionJan 2019
TodayJul 2026
First PostedMar 3, 2016
Enrollment StartJan 1, 2014
Primary CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 10.3 years ago
Interventions
sugammadexdrug
Neostigminedrug